Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status
Sanne Venneker(Leiden University Medical Center), Judith V.M.G. Bovée(Leiden University Medical Center)
Cited by 31
Related Papers
Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation
|British Journal of Cancer|2018|61
Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma
|Oncogenesis|2018|57
Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone
|BMC Cancer|2012|43
Targeting survivin as a potential new treatment for chondrosarcoma of bone
|Oncogenesis|2016|34